Gilead Sciences (NASDAQ:GILD)

mosquito

7 Companies in the Fight to Defeat the Zika Virus

In 2016, it is the Zika virus that has the public worried about the next pandemic. Past scares have been around Ebola, E. coli, SARS, mad cow, swine flu and ...
Read Full Story »
Test tubes

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the May 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Stock Price

The 52-Week Low Club for Thursday

May 19, 2016: Here are four stocks trading with heavy volume among 81 equities making new 52-week lows in Thursday's session. NYSE decliners led advancers by nearly 2 to 1 ...
Read Full Story »
Test tubes

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
graph

Can Gilead Shares Still Really Rise to $150?

Gilead Sciences Inc. (NASDAQ: GILD) recently saw a sell-off after the company posted less than favorable earnings, but one analyst thinks that investors have spoken too soon. This independent analyst ...
Read Full Story »
biotech word cloud

Analysts Make Major Changes to Top Biotech Ratings

At different times of the year, certain sectors come alive or slow down. Typically each year, the first quarter is the slowest for the biotechs, so many analysts tend to ...
Read Full Story »
ThinkstockPhotos-475472230

Top Analyst Upgrades and Downgrades: Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital, Whiting Petroleum and More

Stocks had a rough Thursday and futures were indicated lower on Friday. Despite the drop, we have yet to see any serious selling pressure in a while and investors still ...
Read Full Story »
clinical trials

Gilead Results Trip Over Both the Top and Bottom Lines

Gilead Sciences Inc. (NASDAQ: GILD) reported first-quarter financial results after the markets closed on Thursday. The company had $3.03 in earnings per share (EPS) on $7.79 billion in revenue compared ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Prescription Drugs, Pills

The World’s 15 Top Selling Drugs

Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also help generate billions for drug manufacturers. Pharmaceutical companies generate an ...
Read Full Story »
investing

UBS Makes Major Changes to Equity Focus List for Q2

All the firms we cover on Wall Street have a list of their highest conviction stock ideas for institutional and high net worth clients, and with the second quarter underway, ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the March 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
graph

5 Biotechs With the Most Upside This Earnings Cycle

With earnings just around the corner, one key analyst is taking the opportunity to share its thoughts on select mid-cap and large-cap biotech companies. Despite a modest erosion to fundamentals and sector ...
Read Full Story »
gavel and cash money

How Ionis Pharma Beat a Biotech Giant

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system. The company announced that a jury in the U.S. ...
Read Full Story »
automatic inspection machine

Why One Analyst Sees Gilead Worth 66% More

Gilead Sciences Inc. (NASDAQ: GILD) has been touted by many analysts as being a great value stock with serious upside ahead. Gilead remains the top biotech stock that remains well ...
Read Full Story »